GSK takes new approach to drug checks
08 July, 2003 by Melissa TrudingerPharmaceutical giant GlaxoSmithKline (GSK) is blazing a new trail by using pharmacogenetics approaches for post-approval surveillance of new drugs.
Australia tops world in herbicide resistance
08 July, 2003 by Melissa TrudingerAustralia has the world's most severe herbicide resistance problem, Western Australia's Prof Stephen Powles told delegates at the XIX International Congress of Genetics on Monday.
Why geneticists should go down on the farm
08 July, 2003 by Melissa TrudingerFarm animals provide a unique opportunity to capture genes influencing multi-factorial traits, according to Leif Andersson, who presented the first plenary on Tuesday at the XIX International Congress of Genetics.
Gradipore admits loss, poor communication
08 July, 2003 by Jeremy TorrIn a lengthy shareholders' advice, beleaguered biosensor company Gradipore has donned not just the hair shirt but the hair suit admitting a "disappointing" $15.5-16 million loss and noting commitment to a "more effective and timely communication with all shareholders."
Domestication: it's only natural
07 July, 2003 by Melissa TrudingerDomesticated plant and animal genomes provide excellent material for the study of haplotypes and adaptation, according to Gane Ka-Shu Wong, deputy director of the Beijing Institute of Genomics.
Anti-GM attitude 'paradoxical': Amman
07 July, 2003 by Graeme O'NeillDr Klaus Amman is puzzled by the furore over pollen drift from genetically modified crops - "Pollen did not learn to fly with transgenes," he said.
Poverty, not GM, threatens biodiversity
07 July, 2003 by Graeme O'NeillAfrica's leading molecular geneticist told a forum on genetically modified organisms that poverty, not GM crops, posed the biggest threat to biodiversity around the world.
Freebasing flies point to new treatments for addiction
07 July, 2003 by Melissa TrudingerThe administration of freebase cocaine to fruit flies has uncovered novel pathways central to the development of addiction and may eventually lead to the development of drugs to cure or prevent it.
Pentrix goes to Phase II
04 July, 2003 by Jeremy TorrAustralian Cancer Technology (AustCancer)’s anti-cancer vaccine Pentrix is about to enter critical Phase II trials for its efficacy as a disease delay compound against cancer.
EQiTX appoints new R&D man
04 July, 2003 by Jeremy TorrPerth oil exploration company-turned-biotech EQiTX has signaled a new level of intent for its ambitions with the appointment to its board of ex-Pfizer R&D director Dr Kevin Fahey.
Biotech IPO breaks the drought
04 July, 2003 by Jeremy TorrSelect Vaccines, the first biotech floating an IPO in 2003, has shown the way for investors with a 150 per cent oversubscription from the money market.
Artificial heart trials commenced
03 July, 2003 by Melissa TrudingerThe much-anticipated clinical trial of Ventracor's artificial heart has commenced, with the implantation of the device in the first patient at the Alfred Hospital in Melbourne on the weekend.
Big pharma looking for early-stage partners: GSK exec
03 July, 2003 by Melissa TrudingerPartnering with big pharma was increasingly occurring at the early stage of drug development, including pre-clinical and Phase I, a Melbourne conference was told today.
Biotech to inject life into sugar industry
03 July, 2003 by Pete YoungA $54 million Cooperative Research Centre using biotech to inject fresh life into the economics of the sugar industry is due to open for business next month.
Bresagen sues IMVS for $7million
03 July, 2003 by Jeremy TorrFollowing aborted preclinical trials in the UK, Bresagen is to institute proceedings against pathology agency IMVS (Institute of Medical and Veterinary Science) and others involved in initial trials on potential anti-cancer compound E21R.
